HomeRGLS • NASDAQ
add
Regulus Therapeutics Inc
Previous close
$1.58
Day range
$1.58 - $1.66
Year range
$1.08 - $3.79
Market cap
107.36M USD
Avg Volume
340.05K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | — | — |
Operating expense | 3.95M | 68.92% |
Net income | -11.04M | -57.36% |
Net profit margin | — | — |
Earnings per share | -0.17 | 54.05% |
EBITDA | -12.17M | -67.46% |
Effective tax rate | -0.01% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 94.46M | 153.50% |
Total assets | 104.12M | 138.55% |
Total liabilities | 5.94M | -38.47% |
Total equity | 98.18M | — |
Shares outstanding | 65.47M | — |
Price to book | 1.05 | — |
Return on assets | -28.09% | — |
Return on capital | -29.28% | — |
Cash Flow
Net change in cash
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Net income | -11.04M | -57.36% |
Cash from operations | -11.64M | -86.13% |
Cash from investing | -83.00K | — |
Cash from financing | -744.00K | -105.63% |
Net change in cash | -12.46M | -279.21% |
Free cash flow | -7.71M | -47.96% |
About
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Wikipedia
Founded
Sep 2007
Website
Employees
31